Georgia's Online Cancer Information Center


back

Myelodysplastic Syndromes (MDS) Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Myelodysplastic Syndromes (MDS)
Cancer Type = Myelodysplastic Syndromes (MDS)
NCI ID Cancer Type Trial Name
There are currently 23 active Myelodysplastic Syndromes (MDS) clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04996875
Protocol IDs
CGT9486-20-201
2021-001010-10
NCI-2021-09477
2.
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT03802695
Protocol IDs
OGFT001-001
NCI-2019-01953
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
3.
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT05490446
Protocol IDs
AG946-C-002
NCI-2023-00894
2022-500609-42-00
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
4.
NCORP Trial
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT05473910
Protocol IDs
TSCAN-001
NCI-2022-06900
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
5.
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04849910
Protocol IDs
VBP101
NCI-2022-00073
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
6.
Canakinumab and Darbepoetin Alfa for the Treatment of Lower-Risk Myelodysplastic Syndromes in Patients Who Have Failed Erythropoietin Stimulating Agents
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04798339
Protocol IDs
MCC-20552
NCI-2021-02281
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
7.
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT05143996
Protocol IDs
CLN-049-001
NCI-2021-13598
2020-005195-35
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
8.
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplastic Syndrome-Related Changes
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04802161
Protocol IDs
10434
10434
NCI-2021-01961
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
9.
NCORP Trial
Connect® Myeloid Disease Registry
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT01688011
Protocol IDs
Connect® MDS/AML Registry
Treatment Sites (10)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
Piedmont Columbus Regional
Columbus
10.
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04278768
Protocol IDs
CA-4948-102
NCI-2020-03930
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
11.
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT05552469
Protocol IDs
CDFV890G12101
NCI-2023-01291
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
12.
Highest Dose of Uproleselan in Combination with Fludarabine and Cytarabine for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and that Expresses E-selectin Ligand on the Cell Membrane
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT05146739
Protocol IDs
PEPN2113
PEPN2113
NCI-2021-10020
PEPN2113-APAL2020C
13.
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Cancer Type
Cancer-Related Syndrome, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04904588
Protocol IDs
ACCESS
NCI-2021-06605
14.
Hu8F4 in Treating Patients with Advanced Hematologic Malignancies
Cancer Type
Hematopoietic Malignancies, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT02530034
Protocol IDs
2014-0057
NCI-2015-02131
P-TRP-2447-14
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
15.
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults with Blood Cancers Undergoing Donor Stem Cell Transplant
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT03779854
Protocol IDs
RG1003345
9880
NCI-2018-01752
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
16.
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation for the Treatment of Blood Cancer in Patients Undergoing Donor Stem Cell Transplant
Cancer Type
Cancer-Related Syndrome, Hodgkin Lymphoma, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma
NCT ID
NCT04191187
Protocol IDs
MCC-20131
NCI-2019-08483
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
17.
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04279847
Protocol IDs
INCB 57643-103
NCI-2020-07097
18.
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04245397
Protocol IDs
SX682-MDS-102
NCI-2020-04523
R44HL142389-01
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
19.
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children with Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children’s Oncology Group Study
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04726241
Protocol IDs
APAL2020SC
APAL2020SC
NCI-2021-00056
20.
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Plasma cell neoplasm
NCT ID
NCT03805789
Protocol IDs
CSL964_2001
NCI-2019-03310
2018-000329-29
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
21.
Therapeutic Immune Cells (Gamma-Primed Mesenchymal Stromal Cells) for the Prevention of Acute Graft versus Host Disease after Donor Stem Cell Transplant in Patients with Blood Cancers or Myelodysplastic Syndrome
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04328714
Protocol IDs
CHOA4439-18
NCI-2022-01159
22.
NCORP Trial
Tissue Collection and Natural History Study of Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasms
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT02775383
Protocol IDs
NHLBI-MDS
NCI-2016-00281
Treatment Sites (14)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
23.
Vorinostat in Preventing Graft Versus Host Disease in Children, Adolescents, and Young Adults Undergoing Blood and Bone Marrow Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma
NCT ID
NCT03842696
Protocol IDs
UMCC 2018.081
NCI-2019-04695
HUM00147796
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Find Cancer Care

Survivorship

About Georgia CORE

Education & Resources

Media, News & Events

Patient Navigation

Georgia CORE

 

Georgia CORE bridges the gap between groundbreaking research, educational outreach, and effective advocacy to transform the landscape of cancer care for all Georgians.